Related Experiment Video
Updated: Sep 7, 2025
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma
Piotr Łacina1, Aleksandra Butrym2, Diana Frontkiewicz3
1Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland.
Abstract:
CD147 (basigin, BSG) is a membrane-bound glycoprotein involved in energy metabolism that plays a role in cancer cell survival. Its soluble form is a promising marker of some diseases, but it is otherwise poorly studied. CD147 is overexpressed in multiple myeloma (MM) and is known to affect MM progression, while its genetic variants are associated with MM survival. In the present study, we aimed to assess serum soluble CD147 (sCD147) expression as a potential marker in MM. We found that sCD147 level was higher in MM patients compared to healthy individuals. It was also higher in patients with more advanced disease (ISS III) compared to both patients with less advanced MM and healthy individuals, while its level was observed to drop after positive response to treatment. Patients with high sCD147 were characterized by worse progression-free survival. sCD147 level did not directly correlate with bone marrow CD147 mRNA expression. In conclusion, this study suggests that serum sCD147 may be a prognostic marker in MM.
Insights
Serum soluble CD147 (sCD147) is elevated in multiple myeloma (MM) patients, particularly those with advanced disease. Higher sCD147 levels correlate with poorer progression-free survival, suggesting its potential as a prognostic marker in MM.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- CD147 (basigin, BSG) is a transmembrane glycoprotein crucial for cellular energy metabolism and cancer cell survival.
- While its soluble form (sCD147) shows promise as a disease marker, it remains understudied.
- CD147 overexpression is implicated in multiple myeloma (MM) progression and survival.
Purpose of the Study:
- To evaluate serum soluble CD147 (sCD147) as a potential diagnostic and prognostic biomarker in multiple myeloma (MM).
Main Methods:
- Serum sCD147 levels were measured in MM patients and healthy controls.
- Correlations between sCD147 levels and disease stage (ISS), treatment response, and progression-free survival were analyzed.
- Comparison of serum sCD147 with bone marrow CD147 mRNA expression was performed.
Main Results:
- Serum sCD147 levels were significantly higher in MM patients than in healthy individuals.
- Elevated sCD147 was observed in advanced stage MM (ISS III) and decreased upon successful treatment.
- High sCD147 levels were associated with worse progression-free survival in MM patients.
- No direct correlation was found between serum sCD147 and bone marrow CD147 mRNA expression.
Conclusions:
- Serum sCD147 is a potential prognostic biomarker for multiple myeloma.
- sCD147 levels reflect disease activity and treatment response in MM.
- Further research is warranted to validate sCD147 as a clinical tool in MM management.
